Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat

Journal of Urology

Volumn 162, Issue 1, 1999, Pages 53-57

  Sharma, Shashikala ^a   Zippe, Craig D ^a   Pandrangi, Lakshmi ^a   Nelson, David ^a   Agarwal, Ashok ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antigens, neoplasm; Bladder neoplasms; Carcinoma, transitional cell; Nuclear matrix; Tumor markers, biological

Indexed keywords

TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BLADDER TUMOR; CANCER SCREENING; DIAGNOSTIC ACCURACY; FOREIGN BODY; HUMAN; ILEAL CONDUIT; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; INSTRUMENTATION; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINARY DIVERSION; URINARY TRACT INFECTION; URINARY TRACT INFLAMMATION; URINARY TRACT TUMOR; URINE CYTOLOGY; UROLITHIASIS;

EID: 0032863391     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199907000-00014     Document Type: Article

References (8)

1. Carpinito, G. A., Stadler, W. M., Briggman, J. V., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P. H., Messing, E. M., Pasciak, R. M., Reservitz, G. B., Ross, R. N., Rusktalis, D. B., Sarosdy, M. F., Soloway, M. S., Theil, R. P., Vogelzang, N. and Hayden, C. L.: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol., 156: 1280, 1996.
2. Akaza, H., Miyanaga, N., Tsukamoto, T., Ishikawa, S., Noguchi, R., Ohtani, M., Kawabe, K., Kubota, Y., Fujita, K., Obata, K., Hirao, Y., Kotake, T., Ohmori, H., Kumazawa, J. and Koiso, K.: Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer-screening for urothelial cancer in patients with microscopic hematuria. Jap. J. Cancer Chemother., 24: 837, 1997.
3. Keesee, S. K., Briggman, J. V., Thill, G. and Wu, Y. J.: Utilization of nuclear matrix protein for cancer diagnosis. Crit. Rev. Eukaryotic Gene Express., 6: 189, 1996.
4. Getzenberg, R. H., Konety, B. R., Oeler, T. A., Quigley, M. M., Hakam, A., Beich, M. J. and Bahnson, R. R.: Bladder Cancer-associated Nuclear Matrix Proteins. Cancer Res., 56: 1690, 1996.
5. Sarosdy, M. F., Hudson, M. A., Ellis, W. J., Soloway, M. S., de Vere White, R., Sheinfeld, J., Jarowenko, M. V., Schellhammer, P. F., Schervish, E. W., Patel, J. V., Chodak, G. W., Lamm, D. L., Johnson, R. D., Henderson, M., Adams, G., Blumenstein, B. A., Thoelke, K. R., Pfalzgraf, R. D., Murchison, H. A. and Brunelle, S. L.: Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology, 50: 349, 1997.
6. Zippe, C. D., Pandrangi, L. and Agarwal, A.: NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J. Urol., 161: 62, 1999.
7. Stampfer, D. S., Carpinito, G. A., Rodriguez-Villanueva, J., Willsey, L. W., Dinney, C. P., Grossman, H. B., Fritsche, H. A. and McDougal, W. S.: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol., 159: 394, 1998.
8. Landman, J., Chang, Y., Kavaler, E., Droller, J. M. and Liu, B. C.: Sensitivity and specificity of NMP22, Telomerase, and BTA in the detection of human bladder cancer. Urology, 52: 398, 1998.